Novel Immunotherapy Combination Produces Durable Response in Untreated Metastatic Melanoma
Source: Clinical Omics, July 2021
An unmet need remains for novel immune checkpoint inhibitor combinations that achieve durable and deep responses in patients with metastatic melanoma, without adding substantial toxicity.
Results from the Phase II PIVOT-02 study in untreated metastatic melanoma has shown the combination of interleukin-2 (IL-2) pathway agonist bempegaldesleukin (BEMPEG) plus the immunotherapy nivolumab may fit the bill.
